NMC
SGMO

Nine Masts Capital’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Nine Masts Capital’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$28K Buy
+113,465
New +$45.1K ﹤0.01% 222

Other funds holding SGMO

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Nine Masts Capital's SGMO Position: Q1 2026 in Review

Nine Masts Capital opened a new position in SANGAMO THERAPEUTICS INC (SGMO) in Q1 2026: 113,465 shares worth $28K. The stake represents ﹤0.01% of the portfolio and ranks #222 among its holdings.

112 funds tracked by Wall St. Rank hold SGMO as of Q1 2026.

  • Nine Masts Capital held 113,465 shares of SANGAMO THERAPEUTICS INC worth $28K as of Q1 2026.
  • SANGAMO THERAPEUTICS INC was a new Nine Masts Capital position in Q1 2026.
  • SANGAMO THERAPEUTICS INC made up ﹤0.01% of Nine Masts Capital's portfolio in Q1 2026, its #222 holding.
  • 112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2026.

Based on Nine Masts Capital's 13F filing for Q1 2026, filed 13 May 2026.